Cyteir Therapeutics Inc. (CYT)
Cyteir Therapeutics Statistics
Share Statistics
Cyteir Therapeutics has 36M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 36M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 10.83M |
| Failed to Deliver (FTD) Shares | 1.4K |
| FTD / Avg. Volume | 0.83% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.32 and the forward PE ratio is null. Cyteir Therapeutics's PEG ratio is 0.03.
| PE Ratio | -1.32 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.4 |
| P/FCF Ratio | -1.36 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Cyteir Therapeutics has an Enterprise Value (EV) of -88.03M.
| EV / Sales | 0 |
| EV / EBITDA | 1.85 |
| EV / EBIT | 2.07 |
| EV / FCF | 2.05 |
Financial Position
The company has a current ratio of 28.07, with a Debt / Equity ratio of 0.01.
| Current Ratio | 28.07 |
| Quick Ratio | 28.07 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | 72.11 |
Financial Efficiency
Return on Equity is -30.05% and Return on Invested Capital is -31.23%.
| Return on Equity | -30.05% |
| Return on Assets | -28.68% |
| Return on Invested Capital | -31.23% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-955.48K |
| Employee Count | 46 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -2.11M |
| Effective Tax Rate | 4.58% |
Stock Price Statistics
The stock price has increased by 0.33% in the last 52 weeks. The beta is 0.1, so Cyteir Therapeutics's price volatility has been higher than the market average.
| Beta | 0.1 |
| 52-Week Price Change | 0.33% |
| 50-Day Moving Average | 3.06 |
| 200-Day Moving Average | 2.94 |
| Relative Strength Index (RSI) | 42.39 |
| Average Volume (20 Days) | 167.62K |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.38M |
| Operating Income | -48.17M |
| Net Income | -43.95M |
| EBITDA | -47.5M |
| EBIT | -46.73M |
| Earnings Per Share (EPS) | -1.25 |
Balance Sheet
The company has 147.12M in cash and 889K in debt, giving a net cash position of 146.23M.
| Cash & Cash Equivalents | 147.12M |
| Total Debt | 889K |
| Net Cash | 146.23M |
| Retained Earnings | -138.11M |
| Total Assets | 131.01M |
| Working Capital | 124.67M |
Cash Flow
In the last 12 months, operating cash flow was -42.53M and capital expenditures -312K, giving a free cash flow of -42.84M.
| Operating Cash Flow | -42.53M |
| Capital Expenditures | -312K |
| Free Cash Flow | -42.84M |
| FCF Per Share | -1.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CYT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -75.52% |
| FCF Yield | -73.61% |
Analyst Forecast
Currently there are no analyst rating for CYT.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 9.34 |
| Piotroski F-Score | 1 |